Skip to content

Sections
- Health
- Pharma
- Biotech
- Hospitals
- Politics
- In the Lab
- First Opinion
- Gut Check
- The Watchdogs
Topics
Multimedia
Popular
STAT Plus

Job Board
About Us

Newsletters
My Account
- Settings
- Log Out

Newsletters
My Account
- Settings
- Log Out

Finance

First Opinion

Some tax-exempt hospitals are lax at providing charity care and accountability

By Chuck Grassley

Business

Moderna leaves key questions unanswered as investors seek the reality behind the hype

By Damian Garde

advertisement

First Opinion

Cancer treatment should qualify as a reason for student loan deferment

By Samantha Watson

advertisement

Pharmalot

Lilly will cut 3,500 jobs, or 8 percent of its global workforce, to revamp

By Ed Silverman

Health

St. Kitts launches investigation of herpes vaccine tests on U.S. patients

By Marisa Taylor — Kaiser Health News

First Opinion

A $475,000 price tag for a new cancer drug: crazy or meh?

By Anna Kaltenboeck and Peter B. Bach

Pharmalot

How can Gilead make the Kite deal work? Here’s what the wags say …

By Ed Silverman

advertisement

Adam's Take

4 questions for Gilead and the biotech sector after the $12 billion Kite takeout

By Adam Feuerstein

advertisement

Business

Peter Thiel funds offshore test of herpes vaccine, evading U.S. safety regulations

By Marisa Taylor — Kaiser Health News

Business

Gilead agrees to buy Kite Pharma, leaping into CAR-T cancer therapy

By Adam Feuerstein

Business

Big-name tech investors pour millions into marijuana — both medicinal and not

By Charles Piller

Business

A veteran biopharma executive tries to fund his own product — and sees firsthand how hard it is

By Rebecca Robbins

Politics

Who gets all that biopharma lobbying money?

By Charles Piller

Business

As losses mount, Soon-Shiong’s NantHealth to lay off dozens, reduce headcount by 300

By Rebecca Robbins

Biotech

Why it’s the timing, not the total sum, that matters most in Roivant’s big deal

By Damian Garde

Biotech

Key partner cuts ties with brash biotech startup Moderna, raising big questions about its pipeline

By Damian Garde

Adam's Take

Strong growth in sales of colon cancer test dents the pessimism of Exact Sciences shorts

By Adam Feuerstein

First Opinion

A new wave of pharma mergers could put innovative drugs in the pipeline

By Michael S. Ringel and Michael K. Choy

First Opinion

How Martin Shkreli used social media to fuel his short-selling shenanigans

By Steve Brozak

Biotech

Are short sellers ruining biotech? That’s ‘hogwash,’ analysts say

By Damian Garde

Pharmalot

Should drug makers be banned from buying back stock? Take our reader poll

By Ed Silverman

First Opinion

How much do doctors really make? Compare your salary to various specialties

By Zach Nayer

Biotech

Forget the science. These investors think they can pick biotech winners by algorithm

By Damian Garde

Pharmalot

Teamsters criticize McKesson for ‘excessive’ CEO pay and its role in the opioid crisis

By Ed Silverman

First Opinion

More female leadership: a different kind of health care reform

By Annette Walker

Health

The ice bucket challenge, made famous by ALS patient Pete Frates, raised millions. Here’s how the money was used

By Rebecca Robbins

Biotech

Before a biotech stock debacle, one Republican congressman made a prescient trade

By Damian Garde

Pharmalot

Pharma payments to U.K. docs and hospitals jumped 25 percent, but many docs balk at disclosure

By Ed Silverman

Pharmalot

Allergan to pay $13 million to settle whistleblower lawsuit over kickbacks

By Ed Silverman

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

Industry

Sign up for our morning rounds newsletter

Reporting from the frontiers of health and medicine

About Us
Contact Us
The STAT Team
Work at STAT
Job Board
Advertise

Privacy
Comment Policy
Terms

© 2017 STAT

X